Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of enlicitide chloride (MK-0616) in heterozygous familial hypercholesterolemia
NL-OMON59431Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Oct 2023
- Modality
- Cyclic Peptides → Modified Peptides → Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of enlicitide in heterozygous familial hypercholesterolemia (HeFH), sponsored by Merck & Co. Started Oct 2023; status: completed.
02
Drugs
enlicitide
03
Conditions
heterozygous familial hypercholesterolemia (HeFH)
Beyond the preview
Go deeper on NL-OMON59431.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59431.